MX2016000345A - Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado). - Google Patents

Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).

Info

Publication number
MX2016000345A
MX2016000345A MX2016000345A MX2016000345A MX2016000345A MX 2016000345 A MX2016000345 A MX 2016000345A MX 2016000345 A MX2016000345 A MX 2016000345A MX 2016000345 A MX2016000345 A MX 2016000345A MX 2016000345 A MX2016000345 A MX 2016000345A
Authority
MX
Mexico
Prior art keywords
virus
aav
adeno
assay
associated virus
Prior art date
Application number
MX2016000345A
Other languages
English (en)
Inventor
Katherine A High
Federico Mingozzi
Yifeng Chen
Original Assignee
Philadelphia Children Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Philadelphia Children Hospital filed Critical Philadelphia Children Hospital
Publication of MX2016000345A publication Critical patent/MX2016000345A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14131—Uses of virus other than therapeutic or vaccine, e.g. disinfectant
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/075—Adenoviridae
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/902—Oxidoreductases (1.)
    • G01N2333/90241—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Abstract

Se proporcionan vectores virales, partículas virales y métodos y usos para seleccionar, detectar, analizar y determinar cantidades de anticuerpo antiviral, o actividad de anticuerpos neutralizantes de diversas muestras. Tales vectores virales, partículas virales, y métodos y usos, son aplicables a una amplia variedad de tipos virales, tales como serotipos de lentivirus, adenovirus y virus adenoasociados (AAV). Los métodos y usos incluyen la selección de anticuerpos antivirales, tales como inmunoglobulinas antivirales seleccionadas, detectadas, analizadas y con cantidades determinadas.
MX2016000345A 2013-07-12 2014-07-11 Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado). MX2016000345A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361845841P 2013-07-12 2013-07-12
PCT/US2014/046428 WO2015006743A1 (en) 2013-07-12 2014-07-11 Aav vector and assay for anti-aav (adeno-associated virus) neutralizing antibodies

Publications (1)

Publication Number Publication Date
MX2016000345A true MX2016000345A (es) 2016-06-21

Family

ID=52280652

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016000345A MX2016000345A (es) 2013-07-12 2014-07-11 Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).
MX2021000675A MX2021000675A (es) 2013-07-12 2016-01-11 Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021000675A MX2021000675A (es) 2013-07-12 2016-01-11 Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).

Country Status (12)

Country Link
US (2) US11408899B2 (es)
EP (2) EP4039813A1 (es)
JP (4) JP2016525347A (es)
KR (1) KR102445330B1 (es)
CN (2) CN116004721A (es)
AU (1) AU2014287005C1 (es)
CA (1) CA2918038C (es)
HK (1) HK1222673A1 (es)
IL (1) IL243438B (es)
MX (2) MX2016000345A (es)
RU (1) RU2705249C2 (es)
WO (1) WO2015006743A1 (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164920A1 (en) * 2015-04-09 2016-10-13 Cornell University Gene therapy to prevent reactions to allergens
CA2990193A1 (en) 2015-06-23 2016-12-29 The Children's Hospital Of Philadelphia Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
MX2018005084A (es) 2015-11-05 2019-05-16 Bamboo Therapeutics Inc Genes de ataxia de friedreich modificados y vectores para terapia genica.
US10983110B2 (en) 2015-12-02 2021-04-20 Voyager Therapeutics, Inc. Assays for the detection of AAV neutralizing antibodies
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
US20210228738A1 (en) 2017-07-17 2021-07-29 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins
CN107828821A (zh) * 2017-11-15 2018-03-23 四川大学 一种腺相关病毒感染敏感的细胞系的构建方法及腺相关病毒中和抗体含量测定的检测方法
JP7140353B2 (ja) * 2017-12-29 2022-09-22 ヘリックスミス カンパニー， リミテッド ハイブリッドｈｇｆ遺伝子が導入されたａａｖ（アデノ－関連ウイルス）ベクター
US10610606B2 (en) 2018-02-01 2020-04-07 Homology Medicines, Inc. Adeno-associated virus compositions for PAH gene transfer and methods of use thereof
EP3755795A4 (en) 2018-02-19 2022-07-20 Homology Medicines, Inc. ADENO-ASSOCIATED VIRUS COMPOSITIONS FOR RECOVERING F8 GENE FUNCTION AND METHODS OF USE THEREOF
AU2019249890A1 (en) * 2018-04-05 2020-09-24 Association Institut De Myologie Hybrid recombinant adeno-associated virus serotype between AAV9 and AAVrh74 with reduced liver tropism
CN110846392A (zh) * 2018-08-20 2020-02-28 武汉纽福斯生物科技有限公司 一种重组腺相关病毒或含其的试剂盒及其应用
WO2020102753A1 (en) * 2018-11-16 2020-05-22 Spark Therapeutics, Inc. In vitro assay for detecting enhancers and inhibitors of adeno associated virus (aav) vector transduction and/or detecting or quantitating anti-aav binding antibodies
US20220120759A1 (en) * 2019-01-31 2022-04-21 Rajiv Mahadevan Methods for detection and characterization of anti-viral vector antibodies
TW202140791A (zh) 2020-01-13 2021-11-01 美商霍蒙拉奇醫藥公司 治療苯酮尿症之方法
AU2021213956A1 (en) 2020-01-28 2022-08-25 Freeline Therapeutics Limited Improved assay for determining neutralising antibody titre to a viral vector
BR112023004176A2 (pt) * 2020-09-10 2023-04-11 Genethon Capsídeo de aav modificado por peptídeo
CN112143712B (zh) * 2020-09-30 2022-11-01 中国科学院深圳先进技术研究院 一种重组腺相关病毒及其制备方法和在抗体检测的应用
WO2023114816A1 (en) 2021-12-14 2023-06-22 Neurogene, Inc. Recombinant optimized galc constructs and methods for treating galc-associated disorders
CN114277090A (zh) * 2021-12-17 2022-04-05 宁波熙宁检测技术有限公司 Aav8中和抗体检测方法和检测试剂盒
GB202201242D0 (en) 2022-01-31 2022-03-16 Univ Edinburgh Recombinant optimized mecp2 cassettes and methods for treating rett syndrome and related disorders
WO2023207918A1 (en) * 2022-04-25 2023-11-02 Beijing Hanmoluojie Technology Co., Ltd. Aav capsid 3d molecular surface feature mapping
GB202206336D0 (en) 2022-04-29 2022-06-15 Univ Edinburgh Recombinant therapeutic FMR1 constructs and methods of treating fragile X syndrome and related disorders
WO2023220386A1 (en) * 2022-05-13 2023-11-16 The Children's Hospital Of Philadelphia Adeno-associated viral vectors for targeting brain microvasculature
CN117802161A (zh) * 2022-06-30 2024-04-02 苏州吉恒基因科技有限公司 精准重组腺相关病毒载体及其用途
CN117285620B (zh) * 2023-11-27 2024-02-13 恺佧生物科技(上海)有限公司 抗aav9抗体及aav9滴度测定elisa试剂盒

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL128780A0 (en) 1996-09-06 2000-01-31 Univ Pennsylvania An inducible method for production of recombinant adeno-associated viruses utilizing T7 polymerase
WO1998041240A1 (en) * 1997-03-14 1998-09-24 The Children's Hospital Of Philadelphia Methods and compositions for use in gene therapy for treatment of hemophilia
JP4025400B2 (ja) * 1997-04-16 2007-12-19 財団法人化学及血清療法研究所 新規免疫制御分子及びその製造方法
WO1999061601A2 (en) * 1998-05-28 1999-12-02 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Aav5 vector and uses thereof
DE69936104T2 (de) * 1998-11-05 2008-01-17 The Trustees Of The University Of Pennsylvania Nukleinsäuresequenzen des adeno-assoziierten virus des serotyps i, und vektoren und wirtszellen, die diese enthalten
US6759237B1 (en) * 1998-11-05 2004-07-06 The Trustees Of The University Of Pennsylvania Adeno-associated virus serotype 1 nucleic acid sequences, vectors and host cells containing same
PT1035133E (pt) * 1999-02-17 2005-05-31 Pfizer Prod Inc Proteinas de fusao compreendendo veiculos que podem induzir uma dupla resposta imune
AU7841400A (en) 1999-10-01 2001-05-10 Genovo, Incorporated Production of recombinant aav using adenovirus comprising aav rep/cap genes
US7241447B1 (en) 1999-10-07 2007-07-10 University Of Iowa Research Foundation Adeno-associated virus vectors and uses thereof
ATE318923T1 (de) * 2000-06-01 2006-03-15 Univ North Carolina Doppelsträngige parvovirus-vektoren
CA2481244A1 (en) 2002-04-15 2003-10-23 Universitatsklinikum Hamburg-Eppendorf Recombining viral vectors for the tetracycline-regulated expression of genes
US20070015238A1 (en) * 2002-06-05 2007-01-18 Snyder Richard O Production of pseudotyped recombinant AAV virions
EP1369491A1 (en) * 2002-06-05 2003-12-10 Aladar A. Szalay Light emitting microorganisms and cells for diagnosis and therapy of diseases associated with wounded or inflamed tissue
JP2006505249A (ja) * 2002-06-13 2006-02-16 ワイス・ホールディングズ・コーポレイション 炎症遺伝子活性およびコレステロール生合成の阻害剤
WO2010036339A2 (en) * 2008-09-25 2010-04-01 Duke University A method of detecting antibodies and antibody-hiv virion complexes
EP3421603B1 (en) 2009-05-02 2021-10-06 Genzyme Corporation Gene therapy for neurodegenerative disorders
KR101464902B1 (ko) * 2010-08-20 2014-11-24 나이키 이노베이트 씨.브이. 골프 클럽 및 골프 클럽 헤드
CN102576029A (zh) 2010-10-01 2012-07-11 松下电器产业株式会社 从脂质双层膜的外侧向内侧输送钾离子的方法
US8202687B2 (en) 2010-10-01 2012-06-19 Panasonic Corporation Method for transporting potassium ions from front side to back side of lipid bilayer membrane
BR112013010855A2 (pt) 2010-11-02 2017-06-27 Promega Corp luciferases derivadas de oplophorus, novos substratos de coelenterazina e métodos de uso
EP2675484B1 (en) 2011-02-14 2018-05-30 The Children's Hospital of Philadelphia Improved aav8 vector with enhanced functional activity and methods of use thereof
CN103014064A (zh) 2011-09-22 2013-04-03 北京五加和分子医学研究所有限公司 Itr同向排列的aav载体构建及其应用
JP6348064B2 (ja) * 2011-11-22 2018-06-27 ザ チルドレンズ ホスピタル オブ フィラデルフィア 効率の高いトランスジーン送達のためのウイルスベクター

Also Published As

Publication number Publication date
JP2019162109A (ja) 2019-09-26
EP3019620A4 (en) 2017-01-18
US20220334126A1 (en) 2022-10-20
AU2014287005A1 (en) 2016-01-28
JP2016525347A (ja) 2016-08-25
AU2014287005B2 (en) 2020-12-17
KR102445330B1 (ko) 2022-09-19
IL243438B (en) 2020-02-27
CN105518145A (zh) 2016-04-20
JP2022037027A (ja) 2022-03-08
KR20160034332A (ko) 2016-03-29
CA2918038C (en) 2023-03-28
RU2016104614A (ru) 2017-08-18
HK1222673A1 (zh) 2017-07-07
IL243438A0 (en) 2016-03-31
AU2014287005C1 (en) 2021-06-03
EP4039813A1 (en) 2022-08-10
WO2015006743A1 (en) 2015-01-15
MX2021000675A (es) 2021-03-25
US11408899B2 (en) 2022-08-09
EP3019620A1 (en) 2016-05-18
RU2705249C2 (ru) 2019-11-06
US20160123990A1 (en) 2016-05-05
JP2024026253A (ja) 2024-02-28
CA2918038A1 (en) 2015-01-15
CN116004721A (zh) 2023-04-25
RU2016104614A3 (es) 2018-03-05

Similar Documents

Publication Publication Date Title
MX2021000675A (es) Vector aav y ensayo para anticuerpos neutralizantes anti-aav (virus adenoasociado).
MX2021005727A (es) Ensayo in vitro para detectar potenciadores e inhibidores de la transducción de vectores virales adenoasociados (aav) y/o para detectar o cuantificar anticuerpos de unión anti-aav.
PH12018502389A1 (en) Immunochromatography analysis device for detecting zika virus
WO2014165082A3 (en) Antibodies and methods of detection
WO2014015194A3 (en) Methods for detecting and measuring aggregation
MX2020001227A (es) Composiciones y metodos para detectar y cuantificar la proteina en la celula hospedera en las lineas de celulas y productos de polipeptidos recombinantes.
JO3812B1 (ar) أجسام مضادة ترتبط بالمركب الترابطي البشري للموت المبرمج 1 (pd-l1)
BR112015023894A2 (pt) sistema e método para determinação de propriedades de uma amostra
EA201690731A1 (ru) Анализ igfbp7, имеющий улучшенную характеристику в биологических образцах
BR112015010758A2 (pt) Proteína de ligação de antígeno recombinante, polinucleotídeo isolado, vetor de ácido nucléico, célula do hospedeiro, e, método de detectar ou isolar uma célula que expressa estavelmente uma proteína heterodimérica
WO2014144725A3 (en) Melatonin monoclonal antibody, detection, methods and uses thereof
EA201792289A1 (ru) Способы обнаружения агглютинации и композиции для их осуществления
EA201991506A1 (ru) Системы и способы для тестирования и скрининга с использованием связанных с соединениями субстратов
SA518391028B1 (ar) Cd37 أجسام مضادة واختبارات للكشف عن
GB2560294A (en) Systems and methods for analyzing the characteristics and compositions of a dry cement
EA201891002A1 (ru) Иммунологический анализ для определения расщепленного высокомолекулярного кининогена
MX2017007232A (es) Ensayos de desplazamiento por movilidad homogeneos indirectos para la deteccion de productos biologicos en muestras de pacientes.
BR112017002622A2 (pt) métodos e sistemas para quantificação seletiva e detecção de alergênicos
BR112019009765A2 (pt) anticorpo de ligação à anidrase carbônica e uso do mesmo
BR112018013381A2 (pt) anticorpo especificamente ligante a antígenos derivados de miobacteria ou fragmento ligante a antígeno do mesmo
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение
WO2011116209A3 (en) Using phage epitopes to profile the immune response
WO2014145243A3 (en) High resolution melting analysis assay for the detection of viral dna
MY194325A (en) Test object detection method, and immunoassay instrument and monoclonal antibody for same
MX2016017048A (es) Inmunoensayo reactivo y colaborativo potenciado por enzimas (ceer) usando citometria de flujo.